Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 21, 2026; 32(31): 119706
Published online Aug 21, 2026. doi: 10.3748/wjg.119706
Published online Aug 21, 2026. doi: 10.3748/wjg.119706
Risk factors for low-level viremia in tenofovir disoproxil fumarate-treated chronic hepatitis B patients with advanced hepatic fibrosis/compensated cirrhosis
Run-Ling Zhang, Hai-Ying Zhang, Yu-Yuan Jia, Zhen-Yu Wang, Feng Liu, Hong-Song Chen, Hui-Ying Rao, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on Nonalcoholic Fatty Liver Diagnosis, Infectious Disease and Hepatology Center, Peking University Hepatology Institute, Peking University People’s Hospital, Beijing 100044, China
Hong-Song Chen, Peking University Third Hospital, Beijing 100191, China
Co-first authors: Run-Ling Zhang and Hai-Ying Zhang.
Author contributions: Zhang RL and Zhang HY designed the experiments and completed the manuscript writing and they contribute equally to this study as co-first authors; Jia YY and Wang ZY were responsible for patient enrollment and data collection; Zhang HY and Zhang RL conducted the collation and statistical analysis; Liu F, Chen HS and Rao HY made critical revisions to important knowledge content; all authors have read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Ethical Review Committee of Peking University People's Hospital (Approval No. 2025PHB523-001).
Informed consent statement: This study does not require the signing of an informed consent form, as it employs de-identified data for analysis and adheres to the principles of the Declaration of Helsinki and the ethics committee of the institution agreed to waive informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Hui-Ying Rao, MD, Professor, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on Nonalcoholic Fatty Liver Diagnosis, Infectious Disease and Hepatology Center, Peking University Hepatology Institute, Peking University People’s Hospital, No. 133 Fuchengmennei Street, Xicheng District, Beijing 100044, China. rao.huiying@163.com
Received: February 6, 2026
Revised: March 16, 2026
Accepted: April 15, 2026
Published online: August 21, 2026
Processing time: 179 Days and 21.7 Hours
Revised: March 16, 2026
Accepted: April 15, 2026
Published online: August 21, 2026
Processing time: 179 Days and 21.7 Hours
Core Tip
Core Tip: Our retrospective study enrolled 141 chronic hepatitis B (CHB) patients with advanced hepatic fibrosis/com